Abstract
Voltage-gated calcium channels are key sources of calcium entry into the cytosol. Mutations in calcium channels have been implicated in numerous disorders such as migraine, incomplete congenital X-linked stationary night blindness, epilepsy, and ataxia, and they are important therapeutic targets for the treatment of pain, stroke, hypertension, and epilepsy. Calcium channel antagonists can be broadly classified into three groups. 1) Inorganic ions typically nonselectively block the pore of most calcium channel subtypes, and in some cases, alter gating kinetics. 2) Peptides isolated from arachnids, cone snails, and snakes frequently selectively antagonize individual calcium channel subtypes by direct occlusion of the pore or altering gating kinetics. 3) Small organic molecules of various structure-activityrelationship (SAR) classes can mediate both selective and nonselective effects on individual calcium channel subtypes, and occlude the pore or reduce channel availability. Here, we provide an overview of classes of inhibitors of non-L-type calcium channels.
Keywords: calcium channels, pharmacology, conotoxin, agatoxin, high voltage activated, low voltage activated
Current Pharmaceutical Design
Title: Molecular Pharmacology of Non-L-type Calcium Channels
Volume: 11 Issue: 15
Author(s): Clinton J. Doering and Gerald W. Zamponi
Affiliation:
Keywords: calcium channels, pharmacology, conotoxin, agatoxin, high voltage activated, low voltage activated
Abstract: Voltage-gated calcium channels are key sources of calcium entry into the cytosol. Mutations in calcium channels have been implicated in numerous disorders such as migraine, incomplete congenital X-linked stationary night blindness, epilepsy, and ataxia, and they are important therapeutic targets for the treatment of pain, stroke, hypertension, and epilepsy. Calcium channel antagonists can be broadly classified into three groups. 1) Inorganic ions typically nonselectively block the pore of most calcium channel subtypes, and in some cases, alter gating kinetics. 2) Peptides isolated from arachnids, cone snails, and snakes frequently selectively antagonize individual calcium channel subtypes by direct occlusion of the pore or altering gating kinetics. 3) Small organic molecules of various structure-activityrelationship (SAR) classes can mediate both selective and nonselective effects on individual calcium channel subtypes, and occlude the pore or reduce channel availability. Here, we provide an overview of classes of inhibitors of non-L-type calcium channels.
Export Options
About this article
Cite this article as:
Doering J. Clinton and Zamponi W. Gerald, Molecular Pharmacology of Non-L-type Calcium Channels, Current Pharmaceutical Design 2005; 11 (15) . https://dx.doi.org/10.2174/1381612054021042
DOI https://dx.doi.org/10.2174/1381612054021042 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Docking Studies and Inhibition Properties of Some Antineoplastic Agents against Paraoxonase-I
Anti-Cancer Agents in Medicinal Chemistry Neuromodulation of Hippocampal Synaptic Plasticity, Learning, and Memory by Noradrenaline
Central Nervous System Agents in Medicinal Chemistry Group I Metabotropic Receptor Neuroprotection Requires Akt and Its Substrates that Govern FOXO3a, Bim, and β-Catenin During Oxidative Stress
Current Neurovascular Research Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets AED Strategy after Refractory Epilepsy Surgery
Current Pharmaceutical Design CRISPR/Cas9 in Stem Cell Research: Current Application and Future Perspective
Current Stem Cell Research & Therapy Menthone Aryl Acid Hydrazones: A New Class of Anticonvulsants
Medicinal Chemistry Bryostatin-1 Synergizes with Histone Deacetylase Inhibitors to Reactivate HIV-1 from Latency
Current HIV Research Green Tea, A Medicinal Food with Promising Neurological Benefits
Current Neuropharmacology Novel Therapeutic Targets in Neuropsychiatric Disorders: The Neuroepigenome
Current Pharmaceutical Design Uncovering New Pharmacological Targets to Treat Neuropathic Pain by Understanding How the Organism Reacts to Nerve Injury
Current Pharmaceutical Design On the Discovery and Development of CFTR Chloride Channel Activators
Current Pharmaceutical Design Synthesis and Anticonvulsant Activity of Some Novel Semicarbazone Containing Benzoxazole: Pharmacophore Model Study
Current Bioactive Compounds Mygalin: A New Anticonvulsant Polyamine in Acute Seizure Model and Neuroethological Schedule
Central Nervous System Agents in Medicinal Chemistry Recent Updates on Biological Activities of Oxadiazoles
Mini-Reviews in Medicinal Chemistry Central Nervous System Activities of Indole Derivatives: An Overview
Central Nervous System Agents in Medicinal Chemistry Engineering of Conotoxins for the Treatment of Pain
Current Pharmaceutical Design Kynurenic Acid and Neuroprotective Activity of the Ketogenic Diet in the Eye
Current Medicinal Chemistry Valproic Acid Metabolism and its Consequences on Sexual Functions
Current Drug Metabolism CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets